Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.

A low dose of digoxin ensures that people with heart failure are hospitalized and die less frequently. This emerges from three studies led by UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, ...

A trial by AIIMS shows digoxin may reduce worsening heart failure in rheumatic heart disease patients, offering a low-cost treatment option.